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Abstract
© 2014 American Heart Association, Inc.OBJECTIVE - : Macrophage foam cell formation is a key
feature  of  atherosclerosis.  Recent  studies  have shown that  specific  microRNAs (miRs)  are
regulated in modified low-density lipoprotein-treated macrophages, which can affect the cellular
cholesterol  homeostasis.  Undertaking  a  genome-wide screen of  miRs  regulated in  primary
macrophages by modified low-density lipoprotein, miR-302a emerged as a potential candidate
that may play a key role in macrophage cholesterol homeostasis. APPROACH AND RESULTS - :
The objective of this study was to assess the involvement of miR-302a in macrophage lipid
homeostasis and if it can influence circulating lipid levels and atherosclerotic development when
it  is  inhibited  in  a  murine  atherosclerosis  model.  We  found  that  transfection  of  primary
macrophages with either miR-302a or anti-miR-302a regulated the expression of ATP-binding
cassette (ABC) transporter ABCA1 mRNA and protein. Luciferase reporter assays showed that
miR-302a repressed the 3′ untranslated regions (UTR) activity of mouse Abca1 by 48% and
human  ABCA1  by  45%.  In  addition,  transfection  of  murine  macrophages  with  miR-302a
attenuated  cholesterol  efflux  to  apolipoprotein  A-1  (apoA-1)  by  38%.  Long-term  in  vivo
administration of anti-miR-302a to mice with low-density lipoprotein receptor deficiency (Ldlr)
fed an atherogenic diet led to an increase in ABCA1 in the liver and aorta as well as an increase
in circulating plasma high-density lipoprotein levels by 35% compared with that of control mice.
The anti-miR-302a-treated mice also displayed reduced atherosclerotic plaque size by ≈25%
and a more stable plaque morphology with reduced signs of inflammation. CONCLUSIONS - :
These studies identify miR-302a as a novel modulator of cholesterol efflux and a potential
therapeutic target for suppressing atherosclerosis.
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